帕金森病患者血清中细胞外基质降解生物标志物的诊断价值

Diagnostic value of extracellular matrix degradation biomarkers in serum from patients with Parkinson's disease.

作者信息

Holm Nielsen Signe, Karsdal Morten, Henriksen Kim

机构信息

Nordic Bioscience, Herlev, Denmark.

出版信息

J Neurol Sci. 2025 Jan 15;468:123359. doi: 10.1016/j.jns.2024.123359. Epub 2024 Dec 18.

DOI:10.1016/j.jns.2024.123359

PMID:39724826

Abstract

Parkinson's Disease (PD) is a progressive neurodegenerative condition, which is highly heterogeneous upon diagnosis. Brain extracellular matrix (ECM) accounts for 10-20 % of the total brain volume and is responsible for the physical organization of neuronal and glia cells. Blood-based biomarkers quantifying ECM fragments holds the potential as diagnostic and prognostic biomarkers. Here we evaluated the serum ECM biomarkers C1M, C4M, TUM, SPARC-M and BGM in healthy donors and patients diagnosed with PD. The biomarkers were able to separate between healthy donors and PD patients with an AUC up to 0.926. These pathologically relevant biomarkers could be used as biomarkers in clinical management.

摘要

帕金森病（PD）是一种进行性神经退行性疾病，诊断时具有高度异质性。脑细胞外基质（ECM）占脑总体积的10%-20%，负责神经元和神经胶质细胞的物理组织。定量ECM片段的血液生物标志物有潜力作为诊断和预后生物标志物。在此，我们评估了健康供体和被诊断为PD的患者血清中的ECM生物标志物C1M、C4M、TUM、SPARC-M和BGM。这些生物标志物能够区分健康供体和PD患者，曲线下面积（AUC）高达0.926。这些与病理相关的生物标志物可在临床管理中用作生物标志物。